http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Vedran Stefanovic,Nada Aracic,Damir Roje,Ivana Alujevic Jakus,Marinela Bakotin 연세대학교의과대학 2016 Yonsei medical journal Vol.57 No.5
Purpose: To assess the distribution of births and spontaneous abortions, first-trimester abortion (FTA) and mid-trimester abortion(MTA), in untreated (n=128) and low molecular weight heparin (LMWH) treated pregnancies (n=50) of the same women with inheritedthrombophilias and adverse pregnancy outcome (APO) in previous pregnancies. We particularly investigated the impact ofLMWH on reducing the pregnancy complications in two thrombophilia types, “Conventional” and “Novel”. Materials and Methods: 50 women with inherited thrombophilia (26 Conventional and 24 Novel) and APO in previous pregnancieswere included in the study. Conventional group included factor V Leiden (FVL), prothrombin G20210A (PT) mutations and antithrombin(AT), protein S (PS), and protein C (PC) deficiency, while the Novel group included methylentetrahydrofolate-reductase(MTHFR), plasminogen activator inhibitor-1 (PAI-1), and angiotensin converting enzyme (ACE) polymorphism. APO was definedas one of the following: preterm birth (PTB), fetal growth restriction (FGR), preeclampsia (PE), intrauterine fetal death (IUFD), placentalabruption (PA) and deep venous thrombosis (DVT). Results: There was no difference in distribution of births and spontaneous abortions between Conventional and Novel thrombophiliain untreated pregnancies (χ2=2.7; p=0.100) and LMWH treated pregnancies (χ2=0.442; p=0.506). In untreaed pregnancies thrombophiliatype did not have any impact on the frequency of FTA and MTA (χ2=0.14; p=0.711). In birth-ended pregnancies LMWH treatementreduced the incidence of IUFD (p=0.011) in Conventional and FGR, IUFD, and PTB in Novel thrombophilia group. Conclusion: The equal impact of two thrombophilia types on the pregnancy outcomes and a more favorable effect of LMWH therapyon pregnancy complications in Novel thrombophilia group point the need for Novel thrombophilias screening and the futurestudies on this issue should be recommended.